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Abstract: For dentists, there is little information on malignant tumors and 
complications both because their natural evolution is secondary to treatment, 
despite cancer in children represents 3% of all cancer cases. The goal is to make 
a brief review of the most common neoplasm in children, to identify them and 
find out the oral alterations with highest incidence both as secondary to the 
pathology and as a side effect of treatment. This review analyses various types 
of malignant neoplasms which may occur in this stage of life. They are divided 
into haematological: leukemias, lymphomas and solid tumors. The most com-
mon leukemia is acute lymphoblastic (ALL) followed by acute myeloid and 
granulocytic. Lymphomas develop from the lymphatic system and are divided 
into Hodgkin’s and non-Hodgkin’s. Cancer has become a chronic disease fa-
voring a new group of patients who achieve survival but suffer side effects due 
to therapies, drugs, doses and the child’s characteristics. Oral complications 
appear in 40% of cases and the most frequent are mucositis, opportunistic in-
fection, xerostomia, bleeding, periodontal disease and disorders in the develo-
pment of teeth and jaw. Although cancer is located outside of the maxillofacial 
area, chemotherapy is aggressive for a developing organism. The side effects of 
radiation therapy affect the general and specific area to radiate as well as the 
surrounding organs and tissues. Recently, advances in diagnosis and treatment 
have increased survival from 20% to 80%, with long-term treatment. 
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INTRODUCTION.
The incidence of cancer in children is 3% of all cancers1-3. 
Recent advances in diagnostic techniques and treatment 
increased pediatric patients’ survival from 20% to 80%. 
The most common cancers in children are lymphoblastic 
and myeloid leukemia, retinoblastoma, neuroblastoma and 
Ewing sarcoma. Lymphomas are divided into two types: 
Hodgkin’s lymphoma, with greater incidence in 10 to 
30-year-old people and non-Hodgkin’s lymphoma which is 
most common in children4,5.
In the central nervous system, there is an important 
diversity of cancers such as astrocytoma, medulloblastoma, 
glioma, ependymoma, and primitive neuroectodermal 
tumors6. Rhabdomyosarcoma is the only soft tissue sarcoma 
which affects the muscles in any area. It usually develops 
in the head, neck, pelvis and extremities, especially in male 
children between the ages of 2 and 6 years old. Meanwhile, 
the Wilms’ tumor develops in children younger than 10 
years old6.
Osteosarcoma is the most common bone cancer in 
children. It maily appears in long bones such as the humerus, 
femur and tibia, in subjects between 10 and 25 years old, 
with a higher incidence in males7.
Oral complications represent the main problem caused by 
the treatments in patients with cancer. A 40% of children 
who are receiving chemotherapy develop secondary oral 
problems, lesions and/or complications10 as side effects due to 
its aggressive action on a body in full development8-10.
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 TYPE OF CANCER   TREATMENT
Acute lymphoblastic leukemia  Chemotherapy: L-asparaginase, 
		 Vincristine	and	dexamethasone;	
		 a	fourth	drug	from	the	anthracy	
		 cline	class	is	added	(daunorubicin	
		 and	others	such	as	methotrexate
		 and/or	6-mercaptopurine	too.
  Radiation therapy
  Targeted therapy:	tyrosinekinase	
		 inhibitors	(TKI)	and	imatinib	mesy-
		 late	(Gleevec).
Non-Hodgkin’s Lymphoma Stages I and II:	BFM	chemotherapy
		 with	methotrexate,	6-mercaptopu-
		 rine,	combination	CHOP	(cyclopho-
		 sphamide,	doxorubicin,	vincristine,	
		 and	prednisone)	and	COMP	(cyclo-
		 phosphamide,	vincristine,	metho-		
		 trexate	and	prednisone).
  Stages III and IV: L-asparaginase, 
		 Vincristine	and	dexamethasone;	a
		 fourth	drug	from	the	anthracycline	
		 class	(daunorubicin)	is	added	and
		 others	such	as	methotrexate	and/
		 or	6-mercaptopurine	too.
Osteosarcoma Chemotherapy:	Carboplatin,	cispla-
		 tin,	cyclophosphamide,	doxorubicin,
		 epirubicin,	etoposide,	ifosfamide	
		 and	high-dose	methotrexate	with
		 leucovorin.
Rhabdomyosarcoma Chemotherapy:	monoclonal	anti-
		 body,	dacarbazine,	doxorubicin,
		 epirubicin,	gemcitabine	and	ifosfa-
		 mide.
Astrocytoma Radiotherapy: alkylating
  Chemotherapy: Carboplatin	with	
		 or	without	vincristine,	or	a	combi-
		 nation	of	thioguanine,	procarbazi-
		 ne,	lomustine,	and	vincristine	(PVC);
		 Platinum	and	Temozolomide,	and
		 inhibitory	substances	of	mTOR	
		 (Everolymus,	and	Sirolimus).
		 Vinblastine,	Temosolomida	alone	
		 or	combined	with	irinotecan,	beva-	
		 cizumab,	and	prednisone.	
Acute myeloblastic leukemia Chemotherapy or radiation thera-
  py:	all-trans	retinoic	acid	(tRA)	and
		 arsenic	trioxide.
Lymphoblastic Lymphoma Chemotherapy:	GER-GPOH-NHL-
		 BFM-95:	prednisone,	dexametha-
		 sone,	vincristine,	daunorubicin,	
		 doxorubicin,	L-asparaginase,	cyclo-
		 phosphamide,	cytarabine,	metho-
		 trexate,	mercaptopurine-6,	thiogu-
		 anine-6.	
  Radiotherapy:	GER-GPOH-NHL-		 	
  FM-95
Table 1. Cancer treatment in children.CLINICAL PEDIATRIC MANAGEMENT BE-
FORE CANCER TREATMENT.
In a clinical context, prior to the treatment of cancer, 
it is necessary to consider and execute a series of activi-
ties and related procedures such as taking a thorough 
history, oral exploration with diagnostic tools like in-
tra- and extra-oral X-rays, quantitative sialometric stu-
dies, apart from instructing patients in their proper oral 
hygiene, performing topical applications of f luoride and 
realization of general prophylaxis. It is also necessary to 
observe and treat any chronic inf lammatory lesions of 
the jaws and to eliminate traumatic prosthesis removing 
unrepairable dental pieces altered by disease or trauma. 
Finally the extractions should be carried out at least two 
weeks before starting treatment11,12. 
The preventive program covers motivation for both 
the child and his/her family to practice oral hygiene, 
controlling diet, and bacterial plaque, application of f luor 
and sealers on pits and fissures in erupted molars, when 
necessary. In all cases, regular check-ups for reviewing 
and maintenance are needed12.
TREATMENT.
The treatment for haematological malignancies, leu-
kemias and lymphomas comprises induction, intensifica-
tion and maintenance phases. The ones for maintenance 
will be held for at least two years, with frequent reas-
sessments to detect relapses13 (Table 1).
The acute toxicity associated with the treatment and 
its side effects are very important, especially because of 
the negative impact on children’s quality of life and be-
cause they depend on the drugs used, the length of time 
they have been administered, the dosage and each child’s 
specific characteristics. 
Regarding the skin, the overall effects are alopecia, 
erythema or hyperpigmentation. On the heart, there is 
cardiomyopathy. Regarding the gastrointestinal tract, 
there is anorexia, nausea and vomiting, diarrhea, consti-
pation, mucositis, alteration of taste and gastritis. In the 
liver, there is a hidroelectrolitic alteration due to increa-
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most frequent, they are the most serious, such as pulmo-
nary fibrosis, which decreases the ability of the lung to ex-
change oxygen with the bloodstream, and inf lammatory 
interstitial pneumonitis, which causes frequent manifes-
tations of cough, dyspnea and fever. With respect to the 
reproductive system, there is sterility, amenorrhea and al-
terations of the pubertal development. Kidney disorders 
originate mainly because it is the route of elimination of 
drugs or their metabolites and injuries may occur in this 
track structures due to increased levels of urea and serum 
creatinine. Concerning the bladder, the damage is known 
as hemorrhagic cystitis, and patients present hematuria 
and dysuria. Finally, there is hypersensitivity caused by 
the use of corticoisteroids14,15. 
ORAL COMPLICATIONS DURING TREAT-
MENT.
Complications associated with chemotherapy are the 
result of complex interactions between many factors, such 
as the lethal and sublethal injury in oral tissues which 
are produced by an attenuation of the immune system. 
Therefore, it is the main cause for stomatotoxicity which 
interferes with the normal healing process. It is frequent 
to observe oral mucositis, timely viral, fungal and bac-
terial infections, xerostomia, neuropathies, hemorrhages, 
periodontal disease, and alterations in the development 
of teeth and jaw during the stage of dental and skeletal 
maturation16-18. 
A) Mucositis is caused by chemotherapeutic agents 
and/or by ionizing radiation, which act on the cells in 
their multiplicative phase and form a rapid prolifera-
tion of tissue which causes lesions such as aphthous 
stomatitis19. 
There are two types of mucositis: erythematous and 
ulcerative. Erythematous mucositis typically appears bet-
ween 3 and 5 days post-chemotherapy. Ulcerative muco-
sitis is the most severe, producing inf lammation and ul-
ceration of the mucous membrane. It is painful and starts 
between 3 to 7 days after the beginning of chemotherapy 
and lasts for several days. It begins with an erythema in 
Table 1 (Cont’d). Cancer treatment in children
 TYPE OF CANCER   TREATMENT
Hodgkin’s Lymphoma Chemotherapy:	monoclonal	anti-
		 body.
		 Targeted	radiation	therapy.
  Extra:	antibiotics	and	transfusion
		 of	blood	products.	
Histocytosis Chemotherapy:	methotrexate,
		 Thalidomide;	vinblastine,	predni-
		 sone,	and	cytarabine;	Pamidrona-
		 te,	Cladribine;	Sx	degenerative:	
		 dexamethasone,	retinoic	acid,	IVIG
		 infliximab,	and	cytarabine	with	or	
		 without	vincristine.	
		 Radiotherapy:	psoralen	and	long-
		 wave	ultraviolet	radiation	(PUVA).
  Topical: topical	steroids	and	nitro-
		 gen	mustard.	
Germ cell tumor  Early Stages (I and II):	chemothe-
		 rapy	with	cisplatin	and	VP-16	(eto-
		 poside)	associated	with	bleomycin
		 or	not.
  Advanced stages (III and IV):	che-
		 motherapy	with	cisplatin	combina-
		 tions	and	VP-16	(EP)	or	the	same
		 combination	with	Bleomycin	or	with	
		 cisplatin,	VP-16	and	ifosfamide	(VeIP).
Wilms’ Tumor Stage I: chemotherapy	with	regi-
		 men	EE-4-A	(Vincristine	and	dac-
		 tinomycin,	posnefrectomia).
  Stage II: chemotherapy	with	regi-
		 men	EE-4-A,	regimen	DD-4-A	
		 (Vincristine,	etoposide,	doxorubi-
		 cin)	and	regimen	I	(Vincristine,	
		 Doxorubicin,	cyclophosphamide,		
		 and	etoposide).
  Stage III: chemotherapy	with	re-
		 gimen	DD-4-A	and	regimen	I.
  Stage IV:	chemotherapy	with	re-
		 gimen	DD	-	4	A	and	I.
  Stage V:	chemotherapy	with	regi-
		 men	DD	-	4	A,	I	and	EE	–	-4-A.
sed transaminase and bilirubin levels. Concerning the 
bone marrow, there is anemia and neutropenia. Besides, 
thrombocytopenia appears between 7 and 14 days after 
chemotherapy. Among the neurological effects, there is 
drowsiness, paresthesia, seizures, ataxia, and myalgia. 
As for eyes, there are alterations in the colors and visual 
acuity due to conjunctivitis which is caused by the direct 
action on the ocular conjunctiva and favored by eyelashes 
falling and cataracts. Although lung disorders are not the 
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the soft palate, extending to the buccal mucosa, the be-
lly of the tongue and the f loor of the mouth. Then, it is 
followed by an edema, ulceration with bleeding and/or 
pleural effusion with possibilities of secondary and op-
portunistic infections which can lead to anorexia, with 
evident dehydration and malnutrition20. 
The treatment of mucositis is based on soft mouth 
rinses of water containing calcium bicarbonate, 0.12% 
chlorhexidine and saline solution. Also, it is necessary 
to use drugs to protect the epithelium like aluminum 
and magnesium hydroxide, baking soda, diluted hydro-
gen peroxide and sucralfate suspension. In order to re-
lieve pain and swelling it is required the application of 
topical anesthetics such as dyclonine hydrochloride 1% 
and lidocaine viscous 2%. It is also useful to prescri-
be powerful and conventional anti-inf lammatory drugs 
and painkillers, long-term and broad spectrum systemic 
antibiotics, a soft diet, maintain hydration and avoid 
irritating foods. It is advisable to use humidifiers and 
vaporizers, as well as a correct brushing technique with 
the appropriate instrumentation21-23. 
Mucositis classification according to WHO:
Grade 0: symptoms: None.
Grade 1: symptoms: erythema.
Grade 2: symptoms: erythema, edema or ulcers. The 
patient can eat solid foods.
Grade 3: symptoms: erythema, edema or ulcers. The 
patient can only have liquids.
Grade 4: symptoms: the patient requires enteral or pa-
renteral support.
The side effects of radiation therapy depend on the 
radiated area and the surrounding affected organs and 
tissues. They are alopecia, epitheliitis (skin f lushing and 
tension), frequent drowsiness, headaches, dryness of the 
mouth, dysphagia, alterations of taste and smell as well 
as nausea and vomiting, skin darkening, diarrhea, and 
neuroendocrine toxicity, among others24,25. 
The main chemotherapeutic agents which can produ-
ce mucositis are alkylating agents, antimetabolites, ara-
binosidos, vinca alkaloids, anthracyclines and antitumor 
antibiotics among others26,27. 
B) Xerostomia appears as secondary to quantitative and 
qualitative salivary alterations thereby reducing salivary 
amylase and immunoglobulin A, which leads to an increased 
viscosity, burning and pain in the mouth, difficulty for swa-
llowing dry foods, difficulty in speaking, as well as a decrease 
in taste sensitivity and increased liquid consumption. When 
associated with oral mucositis, there may be ulcerations and 
both pain and opportunistic infections intensify. The sali-
vary flow can be stimulated by chewing gum and sugar-free 
lemon drops, or it is recommended to use saliva substitutes 
and sialogogues28. 
C) Secondary infections are originated due to the bone 
marrow suppression caused by chemotherapy, with quanti-
tative and qualitative changes in the oral microflora, or the 
epithelial barrier. The most frequent are the gram-negative 
bacterial infections which affect both teeth and gums and 
oral mucosa and the symptomatology is masked by myelo-
suppression. 
Fungal infections such as candidiasis have a pseudomem-
branous form characterized by patches or chronic atrophic 
erythematous forms and angular cheilitis. In the most serious 
cases, there may be sepsis caused by hematogenous spread. 
Viral infections usually occur in the form of lesions caused 
by the herpes simplex and zoster, compromising the intraoral 
and perioral mucosa, accompanied by fever and lymphade-
nopathy29. 
D) Thrombocytopenia is a gingival hemorrhage or purpu-
ric lesion in the oral mucosa or skin ecchymosis. In patients 
undergoing chemotherapy, blood studies should be carried 
out before any dental surgical procedure since the haemato-
logical values must be 2,000/mm³ in leukocytes; 500/mm³ 
in neutrophils and 100,000/mm³ in platelets21.
AFTER TREATMENT.
Late effects are caused by the disruption of the cell 
division during the stage of child growth. This can now 
be observed due to the higher survival, and they inten-
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sify the lower the age of therapy initiation is. If there is 
an association of chemotherapy and radiation therapy or 
chemotherapy regimen, the alterations are the following:
A) Due to an abnormal dental development, root shor-
tening, conoid roots, small crowns, enamel hypoplasia, 
intimal tear of the apical root, inhibition of the growth of 
the permanent tooth or only of the root, premature erup-
tion of permanent teeth, early obliteration of the perma-
nent apices, pulp chamber widening, root refinement, 
anodontia, microdontia, delay in dentition and dental 
shortening can be observed30. 
B) Due to rampant caries and demineralization, becau-
se of the rapid formation of cavities or dental erosion cau-
sed by a disruption of the salivary f low and consistency as 
well as by the quality in food, which tends to be doughy 
or liquid in the presence of xerostomia or mucositis31,32. 
C) Due to tooth color alteration, because of the use of 
tetracyclines which change the tooth color when admi-
nistered during the calcification stage33,34. 
D) Due to neurotoxicity, 6% of oral complications 
cause discomfort and pain similar to pulpitis. It is cons-
tant and has an acute onset. It is deep, and mimics tooth 
pain or a burning sensation without apparent cause in the 
teeth or in the mucosa. It involves buccal nerves, with a 
higher incidence in lower molars. Nothing important can 
be found in the clinical examination, and in the radio-
graphic exam, a thickening of the periodontal ligament 
in teeth with pulp alive can be seen35. 
In addition, in patients with head and neck cancer, radia-
tion therapy may irreversibly damage the salivary glands, the 
oral mucosa, the musculature and the alveolar bone causing 
xerostomia, dental disease and osteoradionecrosis36,37. 
High-dose chemotherapy or when administered in 
continuous infusion or in frequent cycles, like therapies 
with methotrexate, 5-f luorouracil, doxorubicin and Ac-
tynomicine D, is more likely to cause mucositis than if it 
is given by the intravenous method38.
RECOMMENDATIONS.
It is necessary to emphasize confirmation of the effecti-
veness of oral preventive protocols, considering them as an 
outline to guarantee and guide the professional before, 
during, and after antineoplastic treatment, since the in-
cidence of oral complications can be reduced by elimina-
ting the sources of infection or irritation using preventive 
measures during the treatment. Risk factors are an unkept 
oral cavity, dental pathology and faulty prostheses which 
must be addressed prior to therapy. In the treatment of 
mucositis, a correct oral hygiene like prophylaxis reduces 
its incidence and severity. For the recovery of the haema-
tologic formula post-chemotherapy, it is recommended 
to use a granulocyte colony-stimulating factor (G-CSF). 
This factor produces competent granulocytes in pedia-
tric patients under treatment with some cytotoxic for any 
neoplasm. Its use allows offsetting neutropenia induced 
by chemotherapy thus preventing secondary infections, 
which can sometimes be fatal. 
Children must be included in the protocols of care 
of the pediatric preventive units of the corresponding 
health-care institutions using individualized tests as 
well as preventive programs to motivate both children 
and their parents to keep oral hygiene, advice them on 
diet, control bacterial plaque and, when required include 
applications of f luoride and pit and fissure sealants and 
schedule periodic follow-up visits.
CONCLUSION.
The pediatric dentist must have an important role 
both in the prevention, cure and control as well as ac-
tively participate in the detection of cancerous lesions, 
especially in early stages, thus avoiding the possible use 
of aggressive surgery treatment, radiation therapy and 
chemotherapy. In the presence of cancer, the patient 
should be referred to the specialist oncologist, and crea-
te a multidisciplinary team which normally includes an 
oncologist, a radiation therapist, a maxillofacial sur-
geon, a pathologist and a pediatric dentist to assess the 
patient and recommend appropriate therapy in order to 
grant relief and eradicate symptoms to improve their 
quality of life. 
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Alteraciones orales en niños con cáncer. Revisión 
del tema.
Resumen: Existe poca información para el odontólogo 
sobre tumores malignos y complicaciones por su evolu-
ción natural como secundaria al tratamiento a pesar de 
ser el cáncer en niños el 3% de todos los cánceres. El ob-
jetivo es hacer una revisión sucinta de las neoplasias más 
frecuentes en niños, identificarlas y conocer las alteracio-
nes orales con mayor incidencia secundarias tanto a la pa-
tología como el efecto secundario del tratamiento. Rea-
lizamos una revisión analizando los diferentes tipos de 
neoplasias malignas que puede presentarse en esta etapa 
de vida, las cuales se dividen en hematológicos: leucemias 
y linfomas y tumores sólidos. La leucemia más frecuen-
te es la linfoblastica aguda (LLA), después la Mieloide 
Aguda, y Granulocítica. Los linfomas se desarrollan del 
sistema linfático, se dividen en Hodgkin y no Hodgkin. 
El cáncer se ha convertido en una enfermedad crónica. 
Ello favorece un nuevo grupo de pacientes que logran su-
pervivencia suficiente para que puedan producirse efectos 
secundarios por las terapias utilizadas, fármacos, dosis y 
las características de cada niño. Las complicaciones orales 
aparecen en un 40%, las más frecuentes: mucositis, infec-
ción oportunista, xerostomía, hemorragias, enfermedad 
periodontal, alteraciones del desarrollo de dientes y maxi-
lar. Aunque el cáncer esté localizado fuera del área maxi-
lofacial, la quimioterapia es agresiva en un organismo en 
desarrollo. Los efectos secundarios de la radioterapia son 
generales y específicos de la zona a irradiar, órganos y te-
jidos circundantes. Últimamente, los avances en diagnós-
tico y tratamiento aumentaron la supervivencia del 20% 
al 80%, con tratamientos a largo plazo. 
Palabras clave: Cáncer, efectos secundarios orales, qui-
mioterapia, radioterapia.
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